Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Impact of Novel Therapeutics on Relapsed/Refractory HL
Am J Hematol; ePub 2017 Jun 9; Bair, et al
Noticeably improved overall survival was observed in relapsed/refractory Hodgkin lymphoma (RR-HL) patients treated with novel therapeutic agents in a retrospective analysis involving 87 individuals.
Investigators looked at outcomes in RR-HL patients who relapsed after autologous stem cell transplantation (ASCT).
Median overall survival with novel agents was ~86 months, vs ~17 months in those not treated with such. Additional factors linked with improved overall survival included:
- Treatment with radiation therapy post-ASCT.
- Chemosensitivity (relapsed vs primary refractory disease).
- Initial response to ASCT (complete remission/partial remission vs stable disease/progressive disease).
- Transplantation after 2009, vs prior to that point.
Bair S, Strelec L, Nagle S, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. [Published online ahead of print June 9, 2017]. Am J Hematol. doi:10.1002/ajh.24792.